Opthea Limited (OPT) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Biotechnologie Branche. Der Hauptsitz des Unternehmens ist in South Yarra, VIC, Australia. Der aktuelle CEO ist Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir,.
OPT hat IPO-Datum 2020-10-16, 33 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.24B.
Opthea Limited is a clinical-stage biopharmaceutical company based in South Yarra, Australia, focused on developing therapies for eye diseases. The company's pipeline is built on intellectual property targeting VEGF-C, VEGF-D, and VEGF Receptor-3 to address conditions involving abnormal blood and lymphatic vessel growth and vascular leakage. Its lead candidate, OPT-302, is a soluble VEGFR-3 inhibitor in clinical development for wet age-related macular degeneration and diabetic macular edema, designed to work alongside VEGF-A inhibitors for improved efficacy in retinal diseases.
